Literature DB >> 22086742

Venlafaxin-associated post-ictal asystole during electroconvulsive therapy.

L Kranaster, C Janke, L Hausner, L Frölich, A Sartorius.   

Abstract

While post-stimulus asystoles occur quite often during electroconvulsive therapy (ECT) post-ictal or post-seizure sinus bradycardias or even asystoles are rare events. We report the case of an 82-year-old female patient with a current major depressive episode, who developed the rare event of a post-ictal asystole of 6 s and 4 ventricular escape beats during ECT. In the past this patient with a bipolar disorder and mild Alzheimer's disease had already been frequently treated with ECT with good success and no adverse events. Relevant comedication was venlafaxin, quetiapine, donepezil and clonidine, anesthesia was performed with ketamine and succinylcholine. Concurrent medication was completely unchanged compared to previous ECT sessions with the exception of venlafaxine, presumably at high serum levels. In summary, in line with some already existing reports, we expect the noradrenergic action of venlafaxin to have contributed substantially to the post-ictal asystole and want to indicate that the combination of ECT and venlafaxin might be harmful--especially in the elderly population. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22086742     DOI: 10.1055/s-0031-1291349

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  2 in total

1.  Heart rate changes during electroconvulsive therapy.

Authors:  Josef Nagler
Journal:  Ann Gen Psychiatry       Date:  2013-06-13       Impact factor: 3.455

2.  Practice of Acute and Maintenance Electroconvulsive Therapy in the Psychiatric Clinic of a University Hospital from Turkey: between 2007 and 2013.

Authors:  Melike Ceyhan Balci Sengul; Ayse Nur Inci Kenar; Ezgi Hanci; İbrahim Sendur; Cem Sengul; Hasan Herken
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-02-29       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.